16:27 EDT Avidity Biosciences files automatic mixed securities shelf
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNA:
- Avidity Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights
- Avidity gets FDA Breakthrough Therapy designation for delpacibart etedesiran
- Amgen upgraded, Peloton downgraded: Wall Street’s top analyst calls
- Avidity Biosciences initiated with a Buy at BofA with multiple catalysts in 2024
- Avidity Biosciences initiated with a Buy at BofA